{
    "clinical_study": {
        "@rank": "73691", 
        "arm_group": [
            {
                "arm_group_label": "Part A letrozole 2.5 mg", 
                "arm_group_type": "Active Comparator", 
                "description": "letrozole 2.5 mg tablet,once daily for 28 days"
            }, 
            {
                "arm_group_label": "Part B letrozole 5.0 mg", 
                "arm_group_type": "Experimental", 
                "description": "letrozole 2.5 mg tablet, two tablets,once daily for 28 days"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to examine how key patient factors, including body size affect\n      how well letrozole suppresses circulating estrogen levels.\n\n      This study has two components:  (1) Part A - an observational phase to evaluate the impact\n      of vitamin D and obesity on estrogen suppression in post-menopausal women already receiving\n      letrozole treatment, and (2) Part B - an interventional phase for women with body mass index\n      (BM) > 25 kg/m2.\n\n      If BMI or other patient factors reduce the effectiveness of letrozole, modifications to\n      treatment recommendations and studies to test higher dosing of letrozole may be needed to\n      maximize the benefit of this treatment and minimize the risk of the breast cancer coming\n      back."
        }, 
        "brief_title": "Aromatase Inhibitor Host Factors Study", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Breast Neoplasms", 
        "condition_browse": {
            "mesh_term": [
                "Breast Neoplasms", 
                "Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Postmenopausal female patients\n\n          -  histological confirmed diagnosis of estrogen receptor and/or progesterone receptor\n             positive breast cancer (Stage I-III) who have completed local therapy\n\n          -  Currently prescribed and taking letrozole 2.5 mg daily for a minimum of 3 months\n\n          -  Willing to provide written informed consent to participate\n\n          -  for the experimental arm:  all of the above and body mass index (BMI) > 25 kg/m2\n\n        Exclusion Criteria:\n\n          -  Known abnormal liver or renal function defined by:\n\n               1. Serum Creatinine > 1.25 times institutional upper limit of normal (ULN) or\n                  Calculated Creatinine Clearance < 40 mL/min\n\n               2. Serum Bilirubin, AST or ALT > 1.5 times ULN\n\n          -  Presence of persistent local or known metastatic cancer"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "140", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 15, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01669343", 
            "org_study_id": "AI Host Factors"
        }, 
        "intervention": {
            "arm_group_label": [
                "Part A letrozole 2.5 mg", 
                "Part B letrozole 5.0 mg"
            ], 
            "description": "Active Comparator Arm receives 2.5 mg letrozole and Experimental Arm receives 5.0 mg letrozole", 
            "intervention_name": "Letrozole", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Letrozole", 
                "Aromatase Inhibitors"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Aromatase Inhibitors", 
        "lastchanged_date": "January 8, 2014", 
        "location": [
            {
                "contact": {
                    "email": "pgoodwin@mtsinai.on.ca", 
                    "last_name": "Pamela J Goodwin, M.D.", 
                    "phone": "416-586-8605"
                }, 
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "M5G 1X5"
                    }, 
                    "name": "Mount Sinai Hospital"
                }, 
                "investigator": {
                    "last_name": "Pamela J Goodwin, MD", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "srikala.sridhar@uhn.ca", 
                    "last_name": "Srikala Sridhar, MD", 
                    "phone": "416-946-2662"
                }, 
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "M5G 1M9"
                    }, 
                    "name": "Princess Margaret Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Carol.Townsley@uhn.on.ca", 
                    "last_name": "Carol Townsley, MD", 
                    "phone": "416-323-6400", 
                    "phone_ext": "3297"
                }, 
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "M5S 1B1"
                    }, 
                    "name": "Women's College Hospital"
                }, 
                "investigator": {
                    "last_name": "Carol Townsley, MD", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "2", 
        "official_title": "Patient-related Predictors of Estrogen Suppression in Postmenopausal Women Using Adjuvant Letrozole", 
        "other_outcome": {
            "measure": "Musculoskeletal Symptoms", 
            "safety_issue": "Yes", 
            "time_frame": "baseline (day 1), day 29 (end of part A) and day 58 (end of part B)"
        }, 
        "overall_contact": {
            "email": "srikala.sridhar@uhn.ca", 
            "last_name": "Srikala Sridhar, M.D.", 
            "phone": "416-946-2662"
        }, 
        "overall_official": {
            "affiliation": "Mount Sinai Hospital, New York", 
            "last_name": "Srikala Sridhar, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Canada: Health Canada", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Change from Baseline in Serum Estradiol at day 28", 
                "safety_issue": "No", 
                "time_frame": "baseline and day 28"
            }, 
            {
                "measure": "Change in Serum Estradiol from baseline and day 28", 
                "safety_issue": "No", 
                "time_frame": "day 58"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01669343"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Plasma Letrozole", 
                "safety_issue": "No", 
                "time_frame": "baseline, day 29 and day 58"
            }, 
            {
                "measure": "Endocrine Symptoms", 
                "safety_issue": "Yes", 
                "time_frame": "baseline, day 29 (end of part A) and day 58 (end of part B)"
            }
        ], 
        "source": "Samuel Lunenfeld Research Institute, Mount Sinai Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Samuel Lunenfeld Research Institute, Mount Sinai Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}